Table 1.
Retrospective studies reporting outcomes after allogeneic SCT in patients with high-risk AML/MDS using recently developed RIC regimens
Treo indicates treosulfan; Clo, clofarabine; REF, refractory; NHL, non-Hodgkin lymphoma; and ALL, acute lymphoblastic leukemia.
